Summary of Findings Table ‐ AbobotulinumtoxinA 50U showed no clear difference in participant assessment success by analysing scores and scales ‐ 4… compared with onabotulinumtoxinA 20U (high certainty).
Summary of Findings Table ‐ AbobotulinumtoxinA 50U showed no clear difference in major adverse events ‐ Any major adverse events (eyelid ptosis,… compared with onabotulinumtoxinA 20U (moderate certainty).
Summary of Findings Table ‐ AbobotulinumtoxinA 50U showed no clear difference in physician assessment of success by analysing scores and scales ‐ 4… compared with onabotulinumtoxinA 20U (high certainty).
Summary of Findings Table ‐ AbobotulinumtoxinA 50U showed no clear difference in total adverse events compared with onabotulinumtoxinA 20U (moderate certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
It is very uncertain whether summary of Findings Table ‐ IncobotulinumtoxinA 24U changes major adverse events compared with onabotulinumtoxinA 24U (very low certainty).
Summary of Findings Table ‐ IncobotulinumtoxinA 24U showed no clear difference in physician assessment of success by analysing scores and scales ‐ 4… compared with onabotulinumtoxinA 24U (low certainty).
It is very uncertain whether summary of Findings Table ‐ IncobotulinumtoxinA 24U changes total adverse events compared with onabotulinumtoxinA 24U (very low certainty).
The review found no eligible studies for this question.
Botulinum neurotoxin B showed no clear difference in proportion of withdrawals due to adverse events compared with placebo (low certainty).
It is very uncertain whether botulinum neurotoxin B changes proportion of participants with adverse events compared with placebo (very low certainty).
Botulinum neurotoxin B leads to higher adverse events: dry mouth compared with placebo (high certainty).
Botulinum neurotoxin B leads to higher adverse events: dysphagia compared with placebo (high certainty).
Summary of Findings Table ‐ OnabotulinumtoxinA 20U probably leads to higher partcipant assessment of success compared with placebo (moderate certainty).
Summary of Findings Table ‐ OnabotulinumtoxinA 20U probably leads to higher major adverse events compared with placebo (moderate certainty).